Artiva Biotherapeutics (ARTV) to Post Earnings on Wednesday

Artiva Biotherapeutics (NASDAQ:ARTV) will likely be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.64) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, analysts expect Artiva Biotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $10.76 on Tuesday. The firm has a market capitalization of $265.99 million, a price-to-earnings ratio of -3.04 and a beta of 2.16. The stock’s 50-day simple moving average is $9.07 and its 200-day simple moving average is $7.57. Artiva Biotherapeutics has a fifty-two week low of $2.22 and a fifty-two week high of $14.53.

Insider Activity

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. purchased 24,944 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $9.93 per share, with a total value of $247,693.92. Following the completion of the purchase, the director owned 17,329,570 shares in the company, valued at approximately $172,082,630.10. This represents a 0.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Over the last ninety days, insiders have acquired 9,907,958 shares of company stock worth $107,688,019 and have sold 53,040 shares worth $477,890. 21.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Artiva Biotherapeutics

Large investors have recently made changes to their positions in the stock. Prelude Capital Management LLC acquired a new position in Artiva Biotherapeutics during the third quarter worth $41,000. Bank of America Corp DE increased its stake in shares of Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth $53,000. Qube Research & Technologies Ltd acquired a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at about $58,000. Finally, Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $67,000.

Analyst Upgrades and Downgrades

ARTV has been the topic of a number of research analyst reports. HC Wainwright boosted their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Wedbush lifted their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Artiva Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.